ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1019

Comparison Of Comorbidity Indexes In a Clinical and Administrative Rheumatoid Arthritis Cohort: A Case For The Rheumatic Diseases Comorbidity Index

Bryant R. England1, Harlan Sayles2, Ted R. Mikuls2, Dannette S. Johnson3 and Kaleb Michaud4, 1Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 2Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 3Rheumatology, Jackson VA and University of Mississippi Medical Center, Jackson, MS, 4Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Comorbidity, disability and morbidity and mortality, ICD-9

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services II & III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Quantifying comorbidities contribution to disability and mortality is important for assessing prognosis and standardizing cohorts in rheumatic disease research.  A comorbidity index has been developed specifically for individuals with rheumatic diseases.  We compared the Rheumatic Diseases Comorbidity Index (RDCI) with the Charlson-Deyo index (CDI) and Functional Comorbidity Index (FCI) using a nationwide cohort of RA patients.

Methods: The RDCI, range 0-9, combines 11 comorbidities: lung disease, hypertension, MI, stroke, heart disease, cancer, fracture, diabetes, depression, GI problem and ulcer.   The predictive value of the RDCI, CDI, FCI, and a generic comorbidity count (COUNT) for outcomes of functional disability and mortality were tested in the Veterans Affairs RA registry by access to administrative ICD9 diagnosis codes.  Functional disability was measured by MD-HAQ.  Comorbidity indices were fixed at baseline values and patient visits were limited to first visits within each of twenty-one six-month phases from January 2003 to March 2013.  Best fit via Cox proportional hazard for mortality and Generalized Estimating Equations for disability models was determined by the Akaike Information Criterion (AIC) where a lower AIC signifies a better model fit.  Indices were compared in three models: a bare model [age, sex, and race]; an admin model [bare+ visit frequency, BMI, prednisone, and MTX]; and clinic model [admin+ ESR, nodules, RF+, and patient activity scale].

Results:  Each index improved the fit of all models (see Figure).  Comorbidity indices decreased AIC most in the bare model and least in the clinic model.  CDI decreased AIC most in the mortality analysis while performing worst in MD-HAQ.  FCI decreased AIC the most in MD-HAQ analysis but performed worst in mortality.  RDCI performed well in both mortality and MD-HAQ analysis.

 Conclusion:   The RDCI quantifies the contribution of comorbidity to both MD-HAQ and mortality well, while other indices were better predictors of only one outcome.   In the first study that compares comorbidity indices with administrative data such as ICD9 codes, RDCI performed well and shows promise for future use in observational studies obtaining data from electronic medical records.  Furthermore, we demonstrate when choosing a comorbidity index, the outcome of interest and the variables within the model should guide index selection.


Disclosure:

B. R. England,
None;

H. Sayles,
None;

T. R. Mikuls,
None;

D. S. Johnson,
None;

K. Michaud,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-comorbidity-indexes-in-a-clinical-and-administrative-rheumatoid-arthritis-cohort-a-case-for-the-rheumatic-diseases-comorbidity-index/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology